GlassScriptPhysician profile
Mahboob Noory
NPI 1528061595
$3,080.91
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,640 · 2020: $1,441.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $512.97 | 2019-2020 | |
| Pfizer INC. | $443.67 | 2019-2020 | |
| Novo Nordisk INC | $336.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $271.97 | 2019-2020 | |
| Amarin Pharma, INC. | $212.62 | 2019-2020 | |
| Lilly USA, LLC | $210.65 | 2019-2020 | |
| Esperion Therapeutics, INC. | $142.72 | 2020 | |
| Amgen INC. | $132.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $125.03 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $111.78 | 2020 | |
| Glaxosmithkline, LLC. | $93.81 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.05 | 2019-2020 | |
| Allergan, INC. | $84.40 | 2019-2020 | |
| Astellas Pharma US INC | $76.72 | 2019-2020 | |
| Antares Pharma, INC. | $42.91 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.07 | 2019 | |
| Upsher-Smith Laboratories LLC | $30.91 | 2020 | |
| Sanofi-Aventis U.S. LLC | $28.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.20 | 2019 | |
| Boston Scientific Corporation | $14.00 | 2019 | |
| Sanofi Pasteur INC. | $12.30 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahboob Noory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.